Juvenilepolyposis syndrome (JPS) is an autosomal dominant condition characterized bypredisposition to hamartomatous polyps in the gastrointestinal (GI) tract,specifically in the stomach, small intestine, colon, and rectum. The term"juvenile" refers to the type of polyp rather than to the age ofonset of polyps. Most individuals with JPS have some polyps by age 20 years;some may have only four or five polyps over their lifetime, whereas others inthe same family may have more than a hundred. If the polyps are left untreated,they may cause bleeding and anemia. Most juvenile polyps are benign; however,malignant transformation can occur. Most of this increased risk is attributedto colon cancer, but cancers of the stomach, upper GI tract, and pancreas havebeen reported. The incidence of colorectal cancer is 17%-22% by age 35 yearsand approaches 68% by age 60 years. The median age is 42 years. The incidenceof gastric cancer is 21% in those with gastric polyps.
JPS isclinically diagnosed if any one of the three following findings is present:more than five juvenile polyps of the colorectum; multiple juvenile polypsthroughout the GI tract; any number of juvenile polyps and a family history ofjuvenile polyps. Juvenile polyps are hamartomas with a distinct histology thatdiffers from that of adenomas. The genes known to be associated with JPS are SMAD4 and BMPR1A. Approximately 20%of individuals with JPS have mutations in SMAD4(18q21.1); approximately 20% have mutations in BMPR1A. Recent studiessuggest that deletion/duplication testing can identify an additional 9%-14% ofmutations in SMAD4. Approximately 75% of individuals with JPS have anaffected parent; approximately 25% of probands with JPS have no previoushistory of polyps in the family and may have the disorder as the result of anew gene mutation.
Acombined syndrome of JPS and hereditary hemorrhagic telangiectasia (HHT)(termed JPS/HHT) may be present in 15%-22% of individuals with an SMAD4mutation. Some clinicians suggest that patients with juvenile polyposis whohave a SMAD4 mutation should bescreened for the vascular lesions associated with hereditary hemorrhagictelangiectasia, especially occult arteriovenous malformations in visceralorgans that may otherwise present suddenly with serious medical consequences.
Click here for the GeneTests summary on this condition.
This test is indicated for:
- Confirmation of a clinical diagnosis of juvenile polyposis syndrome in individuals who have tested negative for sequence analysis
- Individuals at-risk for juvenile polyposis syndrome due to family history who have tested negative for sequence analysis
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.
Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
- Sequencing analysis of the SMAD4 gene is available (UT) and is required before deletion/duplication analysis.
- Prenataltesting is available to individuals who are confirmed carriers ofmutations. Please contact the laboratory genetic counselor to discussappropriate testing prior to collecting a prenatal specimen.